What are the international guidelines for acute and maintenance intravenous immunoglobulin (IVIg) therapy in a patient with myelin oligodendrocyte glycoprotein antibody‑associated disease presenting with acute optic neuritis?

IVIg Treatment Guidelines for MOGAD-Related Optic Neuritis

Acute Phase Treatment

High-dose intravenous methylprednisolone (IVMP) remains the first-line acute treatment for MOGAD optic neuritis, with IVIg reserved as an adjunct therapy when corticosteroids fail or are contraindicated. 1

Primary Acute Management

• Initiate IVMP 1000 mg daily for 3-5 days as the standard acute intervention for MOG-associated optic neuritis 2, 3
• IVIg can be added as adjunct therapy during the acute attack if response to IVMP is inadequate or incomplete 1
• Plasma exchange (10 cycles) represents an alternative escalation strategy when both IVMP and IVIg prove insufficient, particularly in severe bilateral cases with profound visual loss 2

Evidence for Acute IVIg Use

• The evidence base for acute IVIg in MOGAD optic neuritis is limited to case reports and small series; no randomized controlled trials establish its efficacy as monotherapy 1
• IVIg appears most useful as a rescue therapy rather than first-line treatment, given the robust response most patients demonstrate to corticosteroids alone 4, 3

Maintenance/Relapse Prevention Therapy

IVIg is emerging as probably the most effective long-term immunotherapy for preventing relapses in MOGAD, particularly in steroid-dependent patients who relapse during corticosteroid taper. 1

Indications for Maintenance IVIg

• Initiate maintenance IVIg in patients with recurrent MOGAD optic neuritis who experience frequent relapses (≥2 attacks) or demonstrate steroid-dependent disease with flare-ups during taper 1, 5
• Consider IVIg as the preferred steroid-sparing agent when prolonged oral corticosteroids cause unacceptable adverse effects or when rapid corticosteroid taper consistently triggers relapse 5
• The 50-60% relapse rate during corticosteroid taper in MOG-antibody disease necessitates maintenance immunosuppressive therapy in many patients 6

Dosing and Administration

• Standard maintenance dosing follows 2 g/kg divided over 2-5 days, repeated at regular intervals (typically monthly) 1
• In documented cases, maintenance IVIg successfully reduced annual relapse rates from 1.15 to 0.27 attacks per year while permitting reduction of oral prednisolone from 35 mg to 5 mg daily 5

Comparative Effectiveness

• IVIg demonstrates superior efficacy compared to classic immunosuppressants (azathioprine, mycophenolate) in preventing MOGAD relapses, based on emerging clinical experience 1
• Unlike MS-directed therapies (interferon-β, natalizumab), which can paradoxically increase relapse rates in MOGAD, IVIg does not carry this risk 7, 6
• Rituximab represents an alternative biologic option, though individual patients may continue to relapse despite rituximab plus low-dose prednisone 2

Critical Corticosteroid Taper Strategy

Prolonged oral corticosteroid tapering over 3-6 months after the acute attack is essential to prevent early relapse, which occurs frequently with rapid taper. 1

• Extend oral prednisolone taper beyond the typical 2-week course used in MS-related optic neuritis; MOGAD requires a slower, more gradual reduction over months 4, 1
• The high frequency of relapse during early or rapid corticosteroid withdrawal represents a defining characteristic of MOGAD that distinguishes it from MS 4, 5
• Maintenance low-dose oral corticosteroids (5-10 mg prednisolone daily) may be necessary long-term in some patients, though IVIg offers a steroid-sparing alternative 5

Diagnostic Prerequisites Before Treatment

Confirm MOG-IgG seropositivity using cell-based assays with full-length human MOG antigen before committing to long-term immunotherapy; peptide-based ELISA and Western blot are insufficiently specific. 7, 6

• Obtain serum (not CSF) for MOG-IgG testing at initial presentation, as MOG antibodies are predominantly produced extrathecally and serum yields higher sensitivity 6
• Cell-based assays represent the gold-standard methodology; older peptide-based techniques generate false positives and should not guide treatment decisions 7, 6
• Simultaneous testing for AQP4-IgG is mandatory to exclude neuromyelitis optica spectrum disorder, which requires different therapeutic approaches (rituximab preferred over IVIg) 6

Key Clinical Pitfalls to Avoid

• Do not use MS disease-modifying therapies (interferon-β, natalizumab) in MOG-antibody disease—these agents increase relapse rates rather than prevent them 7, 6
• Do not taper corticosteroids rapidly (within 2-4 weeks) as in typical MS optic neuritis; MOGAD requires prolonged taper to avoid rebound relapses 1, 5
• Do not rely on CSF oligoclonal bands to guide diagnosis—MOGAD typically lacks CSF-restricted bands, particularly in European patients, distinguishing it from MS 7, 8
• Do not delay antibody testing until after multiple relapses; early MOG-IgG detection prevents inappropriate use of MS therapies and enables prompt initiation of appropriate immunotherapy 7, 6

Monitoring During IVIg Therapy

• Assess annual relapse rate and corticosteroid dose requirements as primary outcome measures of IVIg efficacy 5
• Optical coherence tomography (OCT) can document optic nerve swelling acutely and retinal nerve fiber layer (RNFL) thinning chronically, potentially serving as a biomarker for treatment response 4
• Visual field testing and visual evoked potentials provide objective evidence of optic nerve function but are less discriminatory for monitoring treatment efficacy 4

Evidence Quality and Gaps

The evidence supporting IVIg in MOGAD optic neuritis derives primarily from retrospective case series and expert consensus rather than randomized controlled trials 1, 5. Establishing optimal acute therapy protocols, defining precise indications for maintenance immunotherapy, and identifying predictors of relapsing disease remain critical research priorities 4. Despite these limitations, the consistent clinical experience showing dramatic reduction in relapse rates with maintenance IVIg, combined with its favorable safety profile, supports its use as the preferred steroid-sparing agent in relapsing MOGAD 1, 5.